Investment analysts at Oppenheimer began coverage on shares of Vera Therapeutics (NASDAQ:VERA – Get Free Report) in a research report issued on Thursday, MarketBeat Ratings reports. The firm set an “outperform” rating and a $26.00 price target on the stock. Oppenheimer’s price target suggests a potential upside of 52.76% from the company’s current price.
Several other equities research analysts have also weighed in on VERA. Cantor Fitzgerald assumed coverage on shares of Vera Therapeutics in a report on Monday, January 8th. They issued an “overweight” rating on the stock. Raymond James assumed coverage on shares of Vera Therapeutics in a report on Monday, December 18th. They issued an “outperform” rating and a $29.00 target price on the stock. Jefferies Financial Group raised shares of Vera Therapeutics from a “hold” rating to a “buy” rating and upped their target price for the stock from $18.00 to $26.00 in a report on Friday, November 10th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of Vera Therapeutics in a report on Wednesday, December 27th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Vera Therapeutics from $25.00 to $22.00 and set an “overweight” rating on the stock in a report on Thursday, November 30th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Vera Therapeutics has an average rating of “Moderate Buy” and an average target price of $24.43.
Vera Therapeutics Trading Down 0.1 %
Shares of VERA stock opened at $17.02 on Thursday. Vera Therapeutics has a 52-week low of $5.95 and a 52-week high of $20.23. The stock has a market cap of $756.20 million, a price-to-earnings ratio of -5.87 and a beta of 0.87. The company has a debt-to-equity ratio of 0.20, a quick ratio of 6.97 and a current ratio of 6.97. The firm has a fifty day moving average of $15.25 and a 200-day moving average of $15.17.
Vera Therapeutics (NASDAQ:VERA – Get Free Report) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.05. On average, equities research analysts forecast that Vera Therapeutics will post -2.2 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Vera Therapeutics news, major shareholder Commodore Capital Lp sold 1,050,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 10th. The shares were sold at an average price of $18.00, for a total transaction of $18,900,000.00. Following the sale, the insider now directly owns 4,400,000 shares in the company, valued at approximately $79,200,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 22.60% of the company’s stock.
Institutional Trading of Vera Therapeutics
Several hedge funds have recently bought and sold shares of VERA. Metropolitan Life Insurance Co NY grew its stake in shares of Vera Therapeutics by 42.2% during the 2nd quarter. Metropolitan Life Insurance Co NY now owns 1,888 shares of the company’s stock worth $30,000 after acquiring an additional 560 shares in the last quarter. UBS Group AG bought a new position in shares of Vera Therapeutics during the 1st quarter worth approximately $47,000. Ameritas Investment Partners Inc. grew its stake in shares of Vera Therapeutics by 163.1% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,792 shares of the company’s stock worth $45,000 after acquiring an additional 1,731 shares in the last quarter. Royal Bank of Canada grew its stake in shares of Vera Therapeutics by 94.8% in the second quarter. Royal Bank of Canada now owns 3,339 shares of the company’s stock valued at $54,000 after buying an additional 1,625 shares in the last quarter. Finally, Amalgamated Bank grew its stake in shares of Vera Therapeutics by 26.0% in the third quarter. Amalgamated Bank now owns 4,189 shares of the company’s stock valued at $57,000 after buying an additional 864 shares in the last quarter. 84.82% of the stock is currently owned by institutional investors and hedge funds.
Vera Therapeutics Company Profile
Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis.